Business context and reporting period
This is ZIOPHARM Oncology, Inc.’s unaudited Form 10-Q for the three months ended March 31, 2020. The filing identifies the issuer as ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP), not Alaunos Therapeutics, Inc.; confirm that this is the intended filing.
ZIOPHARM is a clinical-stage immuno-oncology company developing Sleeping Beauty cell therapies and a Controlled IL-12 platform. It reported no recurring operating revenue and has not generated significant revenue from product sales.
Key financial metrics
| Metric | Q1 2020 | Q1 2019 or comparison |
|---|---|---|
| Revenue | No significant product revenue | No significant product revenue |
| Research and development expense | $12.7 million | $9.5 million; up 34% |
| General and administrative expense | $6.0 million | $4.1 million; up 44% |
| Operating expenses | $18.7 million | $13.6 million |
| Net loss | $18.3 million | $13.4 million |
| Basic and diluted loss per share | $0.09 | $0.08 |
| Operating cash used | $9.9 million | $10.2 million |
| Cash and cash equivalents at period end | $171.0 million | $79.7 million at December 31, 2019 |
| Working capital | $175.0 million | $93.0 million at December 31, 2019 |
At March 31, 2020, total assets were $198.3 million, total liabilities $17.9 million, and accumulated deficit $702.4 million. The filing reports no borrowings; lease liabilities totaled $2.2 million, including current and noncurrent portions. No operating margin is meaningful because the company had no significant revenue.
Material changes versus the prior comparable period
- Net loss increased by $4.9 million year over year as operating expenses rose. R&D costs increased $3.2 million, attributed mainly to gene-therapy trial costs, cell-therapy and licensing/manufacturing costs, and higher employee costs. G&A increased $1.8 million, principally from compensation, legal and facilities costs.
- Operating cash use was slightly lower year over year, despite the larger net loss. Investing cash use was $0.5 million, mainly for Houston office equipment.
- Financing provided $101.7 million, including $88.7 million net from a public offering and $13.0 million net from at-the-market sales. The share count rose from 181.8 million at year-end 2019 to 214.3 million at March 31, 2020.
Outlook, commentary, risks and unusual items
- Management estimated existing cash would fund planned operations into mid-2022, while cautioning that actual needs could be higher and that there were no committed additional funding sources.
- COVID-19 restrictions delayed or threatened clinical work at the NCI and MD Anderson, including trial preparation, site initiation and enrollment. The company implemented work-from-home policies and assumed certain product-engineering runs to mitigate delays. Management’s trial timing expectations were expressly subject to these disruptions.
- Programs included NCI’s Phase 2 Sleeping Beauty TCR trial, Controlled IL-12 trials in recurrent glioblastoma, and CAR-T development with MD Anderson and Eden BioCell. The filing described expected clinical updates and enrollment plans, not financial guidance.
- Key risks include clinical and regulatory failure or delay, manufacturing and supplier constraints, dependence on research and license partners, competition, and the need for additional capital. Equity financing may dilute shareholders; collaboration or licensing could require concessions of rights.
- A material weakness in internal control over financial reporting remained unremediated at March 31, 2020, involving oversight and timely estimation of third-party clinical-trial expenses. Management said the financial statements were fairly presented and described remediation and staff training in progress; disclosure controls were nevertheless deemed ineffective.
- The filing reported no material legal matters expected by management to adversely affect financial position, results or cash flows. It listed $11.5 million of contractual obligations, including leases, CRADA commitments and royalty/license fees; certain license milestones and other contingent payments could arise upon future development or commercial events.
Important facts for investors to verify
- Confirm issuer identity: this filing names ZIOPHARM Oncology, Inc., whereas the request names Alaunos Therapeutics, Inc.
- Reconcile cash disclosures: the financial statements and liquidity discussion report $171.0 million at March 31, 2020, but one risk-factor passage states approximately $101.7 million, which appears inconsistent and should be checked against the filing.
- Track the material weakness remediation and whether subsequent filings report effective controls.
- Monitor cash burn, clinical-trial delays, financing needs, and the effect of further share issuance on dilution and the stated mid-2022 runway.
- Assess trial progress and any updated results against the filing’s stated plans; the filing does not establish that trial outcomes or timelines will be achieved.